NCT05732831 2025-11-14Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid TumorsTango Therapeutics, Inc.Phase 1/2 Recruiting225 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT05215574 2024-10-10Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting130 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT05311618 2024-04-01Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting71 enrolled